PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

PHASE3RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions

Androgen Axis SuppressionProstatectomyProstate Cancer

Interventions

DRUG

Apalutamide

Given by PO

DRUG

Androgen Deprivation Therapy

Given by PO

Trial Locations (2)

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER